Longitudinal MRI findings from the vitamin E and donepezil treatment study for MCI

the Alzheimer’s Disease Cooperative Study (ADCS)

Research output: Contribution to journalArticle

109 Citations (Scopus)

Abstract

The vitamin E and donepezil trial for the treatment of amnestic mild cognitive impairment (MCI) was conducted at 69 centers in North America; 24 centers participated in an MRI sub study. The objective of this study was to evaluate the effect of treatment on MRI atrophy rates; and validate rate measures from serial MRI as indicators of disease progression in multi center therapeutic trials for MCI. Annual percent change (APC) from baseline to follow-up was measured for hippocampus, entorhinal cortex, whole brain, and ventricle in the 131 subjects who remained in the treatment study and completed technically satisfactory baseline and follow-up scans. Although a non-significant trend toward slowing of hippocampal atrophy rates was seen in APOE ∈4 carriers treated with donepezil; no treatment effect was confirmed for any MRI measure in either treatment group. For each of the four brain atrophy rate measures, APCs were greater in subjects who converted to AD than non-converters, and were greater in APOE ∈4 carriers than non-carriers. MRI APCs and changes in cognitive test performance were uniformly correlated in the expected direction (all p < 0.000). Results of this study support the feasibility of using MRI as an outcome measure of disease progression in multi center therapeutic trials for MCI.

Original languageEnglish (US)
Pages (from-to)1285-1295
Number of pages11
JournalNeurobiology of Aging
Volume29
Issue number9
DOIs
StatePublished - Sep 1 2008

Fingerprint

Vitamin E
Atrophy
Disease Progression
Entorhinal Cortex
Brain
Feasibility Studies
North America
Hippocampus
Outcome Assessment (Health Care)
Therapeutics
donepezil
Cognitive Dysfunction

Keywords

  • Alzheimer's disease
  • Brain atrophy
  • Brain atrophy rates
  • Clinical trials
  • Dementia
  • Longitudinal imaging
  • Magnetic resonance imaging
  • Mild cognitive impairment
  • MRI
  • Serial MRI
  • Therapeutic trials

ASJC Scopus subject areas

  • Neuroscience(all)
  • Aging
  • Developmental Biology
  • Geriatrics and Gerontology
  • Clinical Neurology

Cite this

Longitudinal MRI findings from the vitamin E and donepezil treatment study for MCI. / the Alzheimer’s Disease Cooperative Study (ADCS).

In: Neurobiology of Aging, Vol. 29, No. 9, 01.09.2008, p. 1285-1295.

Research output: Contribution to journalArticle

the Alzheimer’s Disease Cooperative Study (ADCS). / Longitudinal MRI findings from the vitamin E and donepezil treatment study for MCI. In: Neurobiology of Aging. 2008 ; Vol. 29, No. 9. pp. 1285-1295.
@article{f24d547ddcc847e6903a18760f5056eb,
title = "Longitudinal MRI findings from the vitamin E and donepezil treatment study for MCI",
abstract = "The vitamin E and donepezil trial for the treatment of amnestic mild cognitive impairment (MCI) was conducted at 69 centers in North America; 24 centers participated in an MRI sub study. The objective of this study was to evaluate the effect of treatment on MRI atrophy rates; and validate rate measures from serial MRI as indicators of disease progression in multi center therapeutic trials for MCI. Annual percent change (APC) from baseline to follow-up was measured for hippocampus, entorhinal cortex, whole brain, and ventricle in the 131 subjects who remained in the treatment study and completed technically satisfactory baseline and follow-up scans. Although a non-significant trend toward slowing of hippocampal atrophy rates was seen in APOE ∈4 carriers treated with donepezil; no treatment effect was confirmed for any MRI measure in either treatment group. For each of the four brain atrophy rate measures, APCs were greater in subjects who converted to AD than non-converters, and were greater in APOE ∈4 carriers than non-carriers. MRI APCs and changes in cognitive test performance were uniformly correlated in the expected direction (all p < 0.000). Results of this study support the feasibility of using MRI as an outcome measure of disease progression in multi center therapeutic trials for MCI.",
keywords = "Alzheimer's disease, Brain atrophy, Brain atrophy rates, Clinical trials, Dementia, Longitudinal imaging, Magnetic resonance imaging, Mild cognitive impairment, MRI, Serial MRI, Therapeutic trials",
author = "{the Alzheimer’s Disease Cooperative Study (ADCS)} and Jack, {Clifford R.} and Petersen, {Ronald C.} and Michael Grundman and Shelia Jin and Anthony Gamst and Ward, {Chadwick P.} and Drahomira Sencakova and Doody, {Rachelle S.} and Thal, {Leon J.} and Ahern, {Geoffrey L} and Carol Kells and Keith Burton and Arthur Schwartz and Charles Echols and Marci Zomok and Lauren Dawson and Brian Ott and Melissa Clemens and Janet Grace and Sultan Darvesh and Joanne Cross and Glenda Sherwood and Lopez, {Grisel J.} and Phyllis Switzer and Neill Graff-Radford and Francine Parfitt and Makarov, {Lauren M.} and Knopman, {David S.} and Bradley Boeve and Nancy Haukom and Martha Mandarino and Diane Mullinax and Ronald Petersen and Serge Gauthier and Donna Amyot and Nunzio Pomara and {de la Pena}, Corazon and {Marsel Mesulam}, M. and Laura Herzog and Jeffrey Kaye and Joyce Lear and Sarah Berman and Kathy Wild and Sandra Black and Joanne Lawrence and Maureen Evans and Howard Feldman and Valarie O'Neill and Karen Gilchrist and David Geldmacher",
year = "2008",
month = "9",
day = "1",
doi = "10.1016/j.neurobiolaging.2007.03.004",
language = "English (US)",
volume = "29",
pages = "1285--1295",
journal = "Neurobiology of Aging",
issn = "0197-4580",
publisher = "Elsevier Inc.",
number = "9",

}

TY - JOUR

T1 - Longitudinal MRI findings from the vitamin E and donepezil treatment study for MCI

AU - the Alzheimer’s Disease Cooperative Study (ADCS)

AU - Jack, Clifford R.

AU - Petersen, Ronald C.

AU - Grundman, Michael

AU - Jin, Shelia

AU - Gamst, Anthony

AU - Ward, Chadwick P.

AU - Sencakova, Drahomira

AU - Doody, Rachelle S.

AU - Thal, Leon J.

AU - Ahern, Geoffrey L

AU - Kells, Carol

AU - Burton, Keith

AU - Schwartz, Arthur

AU - Echols, Charles

AU - Zomok, Marci

AU - Dawson, Lauren

AU - Ott, Brian

AU - Clemens, Melissa

AU - Grace, Janet

AU - Darvesh, Sultan

AU - Cross, Joanne

AU - Sherwood, Glenda

AU - Lopez, Grisel J.

AU - Switzer, Phyllis

AU - Graff-Radford, Neill

AU - Parfitt, Francine

AU - Makarov, Lauren M.

AU - Knopman, David S.

AU - Boeve, Bradley

AU - Haukom, Nancy

AU - Mandarino, Martha

AU - Mullinax, Diane

AU - Petersen, Ronald

AU - Gauthier, Serge

AU - Amyot, Donna

AU - Pomara, Nunzio

AU - de la Pena, Corazon

AU - Marsel Mesulam, M.

AU - Herzog, Laura

AU - Kaye, Jeffrey

AU - Lear, Joyce

AU - Berman, Sarah

AU - Wild, Kathy

AU - Black, Sandra

AU - Lawrence, Joanne

AU - Evans, Maureen

AU - Feldman, Howard

AU - O'Neill, Valarie

AU - Gilchrist, Karen

AU - Geldmacher, David

PY - 2008/9/1

Y1 - 2008/9/1

N2 - The vitamin E and donepezil trial for the treatment of amnestic mild cognitive impairment (MCI) was conducted at 69 centers in North America; 24 centers participated in an MRI sub study. The objective of this study was to evaluate the effect of treatment on MRI atrophy rates; and validate rate measures from serial MRI as indicators of disease progression in multi center therapeutic trials for MCI. Annual percent change (APC) from baseline to follow-up was measured for hippocampus, entorhinal cortex, whole brain, and ventricle in the 131 subjects who remained in the treatment study and completed technically satisfactory baseline and follow-up scans. Although a non-significant trend toward slowing of hippocampal atrophy rates was seen in APOE ∈4 carriers treated with donepezil; no treatment effect was confirmed for any MRI measure in either treatment group. For each of the four brain atrophy rate measures, APCs were greater in subjects who converted to AD than non-converters, and were greater in APOE ∈4 carriers than non-carriers. MRI APCs and changes in cognitive test performance were uniformly correlated in the expected direction (all p < 0.000). Results of this study support the feasibility of using MRI as an outcome measure of disease progression in multi center therapeutic trials for MCI.

AB - The vitamin E and donepezil trial for the treatment of amnestic mild cognitive impairment (MCI) was conducted at 69 centers in North America; 24 centers participated in an MRI sub study. The objective of this study was to evaluate the effect of treatment on MRI atrophy rates; and validate rate measures from serial MRI as indicators of disease progression in multi center therapeutic trials for MCI. Annual percent change (APC) from baseline to follow-up was measured for hippocampus, entorhinal cortex, whole brain, and ventricle in the 131 subjects who remained in the treatment study and completed technically satisfactory baseline and follow-up scans. Although a non-significant trend toward slowing of hippocampal atrophy rates was seen in APOE ∈4 carriers treated with donepezil; no treatment effect was confirmed for any MRI measure in either treatment group. For each of the four brain atrophy rate measures, APCs were greater in subjects who converted to AD than non-converters, and were greater in APOE ∈4 carriers than non-carriers. MRI APCs and changes in cognitive test performance were uniformly correlated in the expected direction (all p < 0.000). Results of this study support the feasibility of using MRI as an outcome measure of disease progression in multi center therapeutic trials for MCI.

KW - Alzheimer's disease

KW - Brain atrophy

KW - Brain atrophy rates

KW - Clinical trials

KW - Dementia

KW - Longitudinal imaging

KW - Magnetic resonance imaging

KW - Mild cognitive impairment

KW - MRI

KW - Serial MRI

KW - Therapeutic trials

UR - http://www.scopus.com/inward/record.url?scp=47049099074&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=47049099074&partnerID=8YFLogxK

U2 - 10.1016/j.neurobiolaging.2007.03.004

DO - 10.1016/j.neurobiolaging.2007.03.004

M3 - Article

VL - 29

SP - 1285

EP - 1295

JO - Neurobiology of Aging

JF - Neurobiology of Aging

SN - 0197-4580

IS - 9

ER -